PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON MELANOMA CLINICAL DEVELOPMENT PROGRAM FOR INVESTIGATIONAL DRUG PV-10

World News: . []

KNOXVILLE TN Dec 06 2018 GLOBE NEWSWIRE -- Provectus OTCQB PVCT today provided several updates on the Companys melanoma drug development program for its lead investigational agent and small molecule oncolytic immunotherapy PV-10 Intrat umoral ...

More news and information about Provectus Biopharmaceuticals Inc.

Published By:

Globe Newswire: 13:30 GMT Thursday 6th December 2018

Published: .

Search for other references to "provectus" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us